

Cocaine Intoxication Market Report 2034: Epidemiology Data, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Cocaine Intoxication companies are Tonix Pharmaceutical, and others.

LAS VEGAS, NEVADA, UNITED STATES, July 10, 2024 /EINPresswire.com/ -- DelveInsight's "Cocaine Intoxication Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Cocaine Intoxication, historical and forecasted epidemiology as well as the Cocaine Intoxication market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Cocaine Intoxication market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Cocaine Intoxication Market Forecast](#)

Some of the key facts of the Cocaine Intoxication Market Report:

The Cocaine Intoxication market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

Cocaine intoxication presents a multifaceted challenge, encompassing medical emergencies, societal impacts, addiction, and the need for comprehensive strategies addressing prevention, treatment, and harm reduction.

The projected rise in emergency visits due to cocaine in the US may stem from shifting drug trends, economic factors, policy changes, mental health issues, and accessibility to treatment. The United States showed the highest emergency visits population of cocaine compared to other 7MM countries. As per DelveInsight's estimates, in 2023, the country alone accounts for ~56% of total emergency visits due to cocaine, in the 7MM countries.

In 2023, the market size of Cocaine Intoxication was highest in the US among the 7MM accounting for approximately USD 84 million that is further expected to increase by 2034.

Despite of high number of emergency visits for cocaine use of around 981 thousand in 2023 in

the 7MM, the treatment market of Cocaine Intoxication lacks approved therapy specific to Cocaine Intoxication treatment.

Potential launch of emerging therapies have the potential to create a significant positive shift in the Cocaine Intoxication market size.

Key Cocaine Intoxication Companies: Tonix Pharmaceutical, and others

Key Cocaine Intoxication Therapies: TNX-1300, and others

The Cocaine Intoxication market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cocaine Intoxication pipeline products will significantly revolutionize the Cocaine Intoxication market dynamics.

Cocaine Intoxication Overview

Intoxication from excessive cocaine ingestion presents with a range of alarming symptoms, including rapid heart rate, elevated blood pressure, severe agitation, and paranoia. This dangerous condition poses significant challenges, from the risk of overdose to potential cardiac arrest. Compounded by concurrent polydrug use and underlying mental health issues, addressing its impact requires multifaceted strategies involving vigilant monitoring, targeted interventions, and comprehensive support systems.

Accurately diagnosing cocaine intoxication is complex due to its varied presentation and rapid metabolism. Essential laboratory tests such as urine toxicology screens and troponin assays play a crucial role, despite potential limitations like false negatives. Differentiating cocaine-induced symptoms from those of concurrent conditions such as rhabdomyolysis or meningitis demands meticulous evaluation. While imaging techniques can detect severe complications like intracranial hemorrhage, they may not always reveal subtle abnormalities. Prompt assessment is critical for identifying swallowed packets or assessing the risk of myocardial infarction. Clinical judgment is pivotal in navigating overlapping symptoms and potential adverse outcomes, necessitating a nuanced diagnostic approach.

Therapeutic interventions for cocaine intoxication primarily focus on managing acute symptoms and preventing complications. Fundamental supportive care includes stabilizing vital signs, ensuring hydration, and monitoring cardiac and neurological functions. Benzodiazepines may be administered to alleviate agitation and seizures, while antihypertensive medications help control elevated blood pressure. In severe cases, advanced cardiac support or interventions for intracranial hemorrhage may be required. Despite the absence of specific antidotes, symptom-based management and close medical supervision are crucial throughout the recovery process.

Cocaine Intoxication Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed

patient pool and future trends.

As the market is derived using the patient-based model, the Cocaine Intoxication epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Emergency Visits due to Cocaine in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

The total emergency visits due to cocaine in the US are expected to increase with a significant CAGR by 2034, from around 550 thousand cases in 2023 in the US.

Among the EU4 and the UK, Spain (35%) had the highest emergency visits due to cocaine, followed by France in 2023. On the other hand, Germany had the least emergency visits due to cocaine around 3% in the same year.

In 2023, Japan accounted for around 122 thousand emergency visits due to cocaine.

Cocaine Intoxication Epidemiology Segmentation:

The Cocaine Intoxication market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Cocaine Intoxication

Prevalent Cases of Cocaine Intoxication by severity

Gender-specific Prevalence of Cocaine Intoxication

Diagnosed Cases of Episodic and Chronic Cocaine Intoxication

Download the report to understand which factors are driving Cocaine Intoxication epidemiology trends @ [Cocaine Intoxication Epidemiology Forecast](#)

Cocaine Intoxication Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cocaine Intoxication market or expected to get launched during the study period. The analysis covers Cocaine Intoxication market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cocaine Intoxication Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cocaine Intoxication Key Companies

TNX-1300

Cocaine Intoxication Companies

Tonix Pharmaceutical

Cocaine Intoxication Market Outlook

Antipsychotics such as haloperidol and olanzapine can be beneficial in treating symptoms of acute cocaine intoxication. According to the 2008 AHA scientific statement on cocaine-associated

chest pain and myocardial infarction, benzodiazepines are categorized as Class I-B, and in the most recent ACC/AHA guideline for managing non-ST-elevation acute coronary syndrome, they are classified as Class IIa-C. Combination therapy using benzodiazepines along with antipsychotics has shown greater effectiveness compared to monotherapy.

Non-dihydropyridine calcium channel blockers like diltiazem and verapamil are reliable in reducing hypertension but do not effectively treat tachycardia. Dihydropyridine agents such as nifedipine should be avoided due to the potential for reflex tachycardia.

Phentolamine, an alpha-blocker, is recommended for alpha-mediated hypertension but does not address tachycardia effectively. However, it is infrequently used, partly due to clinician unfamiliarity with its administration and dosing. Alpha-1 blockers are not included in the recent ACC/AHA guidelines as they do not improve tachycardia.

Nitric-oxide mediated vasodilators such as nitroglycerin and nitroprusside effectively lower blood pressure, but their use should consider the risk of reflex tachycardia.

Most research on treating hyperadrenergic symptoms from cocaine involves β -blockers, although human trials and case reports do not support their use during intoxication. Labetalol, a mixed β/α blocker, is considered safe and effective for managing cocaine-induced hypertension and tachycardia without causing "unopposed alpha-stimulation." Its use for treating cocaine-associated chest pain is designated as Class IIb-C in the 2013 ACC/AHA guideline.

Agitation and psychosis often co-occur in patients with hyperadrenergic symptoms from acute cocaine toxicity. Dopaminergic receptor antagonists such as haloperidol, droperidol, ziprasidone, olanzapine, risperidone, and aripiprazole are commonly used to control these symptoms, though their effects on blood pressure and heart rate remain uncertain.

Diphenhydramine is frequently added to enhance sedation and prevent dystonia and akathisia. Hyperthermia resulting from cocaine toxicity is best managed with external cooling measures.

Emergency management of cocaine intoxication is challenging due to its complex presentation and potential complications. There is no single cure, and after addressing the acute issues, specific outpatient follow-up is generally lacking, leading to potential patient readmissions within a year. Therefore, rehabilitation is essential, beginning with detoxification involving plasma and liver cholinesterases.

Managing cocaine intoxication remains challenging without approved drugs for prevention or cure. However, Tonix Pharmaceuticals is developing TNX-1300, a recombinant protein enzyme produced using rDNA technology in a non-disease-producing strain of E. coli bacteria, for the treatment of cocaine intoxication. TNX-1300 has received Breakthrough Therapy designation from the FDA, offering hope for addressing this challenging condition.

Cocaine Intoxication Market Insights

The total market size of Cocaine Intoxication in the 7MM was approximately USD 126 million in 2023 and is projected to increase during the forecast period (2024-2034).

The market size in the 7MM will increase at a constant CAGR due to increasing awareness of the disease, better diagnosis, decreasing stigma, and the launch of the emerging target therapy for Cocaine Intoxication.

Among EU4 and the UK, Spain with a share of 35% accounted for the maximum market size in 2023 while Germany occupied the bottom of the ladder with a share of 3% in 2023.

In 2023, Japan held the third-largest share, approximately 10%, of the Cocaine Intoxication treatment market among the seven major markets (7MM).

Scope of the Cocaine Intoxication Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Cocaine Intoxication Companies: Tonix Pharmaceutical, and others

Key Cocaine Intoxication Therapies: TNX-1300, and others

Cocaine Intoxication Therapeutic Assessment: Cocaine Intoxication current marketed and Cocaine Intoxication emerging therapies

Cocaine Intoxication Market Dynamics: Cocaine Intoxication market drivers and Cocaine Intoxication market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Cocaine Intoxication Unmet Needs, KOL's views, Analyst's views, Cocaine Intoxication Market Access and Reimbursement

To know more about Cocaine Intoxication companies working in the treatment market, visit @ [Cocaine Intoxication Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Cocaine Intoxication Market Report Introduction
2. Executive Summary for Cocaine Intoxication
3. SWOT analysis of Cocaine Intoxication
4. Cocaine Intoxication Patient Share (%) Overview at a Glance
5. Cocaine Intoxication Market Overview at a Glance
6. Cocaine Intoxication Disease Background and Overview
7. Cocaine Intoxication Epidemiology and Patient Population
8. Country-Specific Patient Population of Cocaine Intoxication
9. Cocaine Intoxication Current Treatment and Medical Practices
10. Cocaine Intoxication Unmet Needs
11. Cocaine Intoxication Emerging Therapies
12. Cocaine Intoxication Market Outlook
13. Country-Wise Cocaine Intoxication Market Analysis (2020–2034)
14. Cocaine Intoxication Market Access and Reimbursement of Therapies

15. Cocaine Intoxication Market Drivers
16. Cocaine Intoxication Market Barriers
17. Cocaine Intoxication Appendix
18. Cocaine Intoxication Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Cocaine Intoxication Pipeline

"Cocaine Intoxication Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cocaine Intoxication market. A detailed picture of the Cocaine Intoxication pipeline landscape is provided, which includes the disease overview and Cocaine Intoxication treatment guidelines.

Cocaine Intoxication Epidemiology

DelveInsight's 'Cocaine Intoxication Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cocaine Intoxication epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726448147>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.